Site Editor

Sandy Srinivas, MD


Scott T. Tagawa, MD, on Clinical Implications of Using an Anti-PSMA Antibody With Ketoconazole, Hydrocortisone, and Lutetium-177 in Treatment of Prostate Cancer

Posted: Wednesday, March 8, 2023

Scott T. Tagawa, MD, of Weill Cornell Medicine, NewYork-Presbyterian Hospital, discusses practical clinical questions raised by phase II findings showing that the anti-PSMA (prostate-specific membrane antibody) monoclonal antibody J591, when combined with ketoconazole and hydrocortisone and radiolabeled with lutetium-177 (vs. indium-111), may lead to improved 18-month metastasis-free survival for patients with high-risk, low-volume prostate cancer. This supports the development of anti-PSMA radioimmunotherapy, though the optimal radionuclide and targeting agent are still unknown.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.